NASDAQ: ONC
Beone Medicines Ltd Stock

$399.70-3.90 (-0.97%)
Updated Nov 19, 2026
ONC Price
$399.70
Fair Value Price
N/A
Market Cap
$45.70B
52 Week Low
$253.95
52 Week High
$424.73
P/E
644.68x
P/B
7.85x
P/S
6.3x
PEG
0.78x
Dividend Yield
N/A
Revenue
$6.61B
Earnings
$915.57M
Gross Margin
89.4%
Operating Margin
19.93%
Profit Margin
13.9%
Debt to Equity
0.7
Operating Cash Flow
$2B
Beta
0.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ONC Overview

BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ONC's potential to beat the market

AStrong Buy
  • Stocks with a Zen Rating of Strong Buy (A) had an average return of +28.50% per year. Learn More

Zen Rating Component Grades

B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ONC
Ranked
#4 of 448

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ONC news, forecast changes, insider trades & much more!

ONC News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ONC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ONC ($399.70) is trading above its intrinsic value of $154.79, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ONC is poor value based on its earnings relative to its share price (644.68x), compared to the US market average (41.92x)
P/E vs Market Valuation
ONC is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more ONC due diligence checks available for Premium users.

Valuation

ONC price to earnings (PE)

For valuing profitable companies with steady earnings

Company
644.68x
Industry
16.94x
Market
41.92x
ONC is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ONC is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

ONC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
7.85x
Industry
4.88x
ONC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ONC price to earnings growth (PEG)

For valuing profitable companies with growth potential

ONC is good value based... subscribe to Premium to read more.
PEG Value Valuation

ONC's financial health

Profit margin

Revenue
$1.9B
Net Income
$384.7M
Profit Margin
20.4%
ONC's Earnings (EBIT) of $1.32B... subscribe to Premium to read more.
Interest Coverage Financials
ONC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$9.9B
Liabilities
$4.1B
Debt to equity
0.7
ONC's short-term assets ($7.93B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ONC's short-term assets ($7.93B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ONC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ONC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$508.7M
Investing
-$35.8M
Financing
$102.2M
ONC's operating cash flow ($1.59B)... subscribe to Premium to read more.
Debt Coverage Financials

ONC vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ONCA$45.70B-0.97%644.68x7.85x
RPRXA$38.84B-1.38%44.26x3.97x
RVMDC$34.48B-0.24%-17.44x14.36x
ARGXC$58.91B+0.08%29.87x6.16x
GMABC$32.05B+0.75%43.12x5.06x

Beone Medicines Stock FAQ

What is Beone Medicines's quote symbol?

(NASDAQ: ONC) Beone Medicines trades on the NASDAQ under the ticker symbol ONC. Beone Medicines stock quotes can also be displayed as NASDAQ: ONC.

If you're new to stock investing, here's how to buy Beone Medicines stock.

What is the 52 week high and low for Beone Medicines (NASDAQ: ONC)?

(NASDAQ: ONC) Beone Medicines's 52-week high was $424.73, and its 52-week low was $253.95. It is currently -5.89% from its 52-week high and 57.4% from its 52-week low.

How much is Beone Medicines stock worth today?

(NASDAQ: ONC) Beone Medicines currently has 1,484,939,031 outstanding shares. With Beone Medicines stock trading at $399.70 per share, the total value of Beone Medicines stock (market capitalization) is $45.70B.

Beone Medicines stock was originally listed at a price of $28.32 in Feb 3, 2016. If you had invested in Beone Medicines stock at $28.32, your return over the last 10 years would have been 1,311.37%, for an annualized return of 30.31% (not including any dividends or dividend reinvestments).

How much is Beone Medicines's stock price per share?

(NASDAQ: ONC) Beone Medicines stock price per share is $399.70 today (as of Nov 19, 2026).

What is Beone Medicines's Market Cap?

(NASDAQ: ONC) Beone Medicines's market cap is $45.70B, as of Nov 20, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Beone Medicines's market cap is calculated by multiplying ONC's current stock price of $399.70 by ONC's total outstanding shares of 1,484,939,031.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.